Sutro Biopharma (STRO) stock falls as the company announces portfolio review, CEO appointment and headcount reduction. Read ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Fintel reports that on March 14, 2025, Citizens Capital Markets downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement ...

MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or ...

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Sutro completed its review as it widened its loss and posted lower revenue in 2024. The company posted a loss of $227.5 million last year, compared with a loss of $106.8 million in 2023. On a ...

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...

TAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) -- New-generation Contract Development and Manufacturing Organization (CDMO) ...